| 000 | 01696 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250516131833.0 | ||
| 264 | 0 | _c20130522 | |
| 008 | 201305s 0 0 eng d | ||
| 022 | _a1529-0131 | ||
| 024 | 7 |
_a10.1002/art.37850 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aSt Clair, E William | |
| 245 | 0 | 0 |
_aRituximab therapy for primary Sjögren's syndrome: an open-label clinical trial and mechanistic analysis. _h[electronic resource] |
| 260 |
_bArthritis and rheumatism _cApr 2013 |
||
| 300 |
_a1097-106 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal, Murine-Derived _xadverse effects |
| 650 | 0 | 4 |
_aAutoantibodies _xblood |
| 650 | 0 | 4 |
_aB-Lymphocytes _xcytology |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFlow Cytometry |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunologic Factors _xadverse effects |
| 650 | 0 | 4 | _aLymphocyte Count |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aProspective Studies |
| 650 | 0 | 4 | _aRituximab |
| 650 | 0 | 4 |
_aSjogren's Syndrome _xblood |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aLevesque, Marc C | |
| 700 | 1 | _aPrak, Eline T Luning | |
| 700 | 1 | _aVivino, Frederick B | |
| 700 | 1 | _aAlappatt, Chacko J | |
| 700 | 1 | _aSpychala, Meagan E | |
| 700 | 1 | _aWedgwood, Josiah | |
| 700 | 1 | _aMcNamara, James | |
| 700 | 1 | _aMoser Sivils, Kathy L | |
| 700 | 1 | _aFisher, Lytia | |
| 700 | 1 | _aCohen, Philip | |
| 773 | 0 |
_tArthritis and rheumatism _gvol. 65 _gno. 4 _gp. 1097-106 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1002/art.37850 _zAvailable from publisher's website |
| 999 |
_c22433984 _d22433984 |
||